|
26 Oct 2020 |
Olema Oncology Announces Clinical Collaboration to Evaluate OP-1250 in Combination with Advanced Breast Cancer Therapies
|
|
26 Oct 2020 |
Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020
|
|
26 Oct 2020 |
Rivaroxaban application submitted to U.S. FDA for new indication in patients after lower-extremity revascularization due to symptomatic PAD
|
|
26 Oct 2020 |
Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium
|
|
26 Oct 2020 |
Mirati Therapeutics Reports Investigational Adagrasib (MRTX849) Preliminary Data Demonstrating Tolerability and Durable Anti-Tumor Activity as well as Initial MRTX1133 Preclinical Data
|
|
26 Oct 2020 |
Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302, a JAK1 Inhibitor for the Treatment of Moderate-to-Severe Atopic Dermatitis
|
|
26 Oct 2020 |
PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy
|
|
26 Oct 2020 |
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
|
|
26 Oct 2020 |
Forma Therapeutics Announces Positive Top-line Olutasidenib Data From a Planned Interim Analysis of a Registrational Phase 2 Clinical Trial in Acute Myeloid Leukemia (AML)
|
|
26 Oct 2020 |
Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)
|
|
25 Oct 2020 |
Aileron Therapeutics Announces Proof-of-Concept Clinical Data from Ongoing ALRN-6924 Phase 1b Trial Presented in Late-Breaking Presentation at the EORTC-NCI-AACR Annual Symposium
|
|
25 Oct 2020 |
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
|
|
25 Oct 2020 |
Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium
|
|
25 Oct 2020 |
Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting
|
|
25 Oct 2020 |
Farxiga DAPA-CKD Phase III trial reduced worsening of kidney function, risk of cardiovascular or renal death in patients with chronic kidney disease, irrespective of underlying cause
|
|
25 Oct 2020 |
Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes
|
|
23 Oct 2020 |
Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer
|
|
23 Oct 2020 |
LEO Pharma Announces U.S. FDA Approval for Enstilar® (calcipotriene and betamethasone dipropionate) Foam U.S. Prescribing Information Update to Include Data in Long-term Use in Plaque Psoriasis Treatment
|
|
23 Oct 2020 |
Goldfinch Bio Presents Clinical Data from Phase 1 Trial Supporting Advancement of GFB-887 as a Precision Medicine for Patients with Kidney Diseases
|
|
23 Oct 2020 |
U.S. Food and Drug Administration Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19
|
|
22 Oct 2020 |
Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19
|
|
22 Oct 2020 |
STORM Therapeutics selects first-in-class clinical candidate targeting METTL3
|
|
22 Oct 2020 |
Novartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)
|
|
22 Oct 2020 |
UCB’s anti-epileptic drug VIMPAT[®] (lacosamide) receives EU CHMP positive opinion for primary generalised tonic-clonic seizures
|
|
21 Oct 2020 |
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
|
